NO20064576L - Pyrimidine derivatives for the treatment of aberrant cell growth - Google Patents
Pyrimidine derivatives for the treatment of aberrant cell growthInfo
- Publication number
- NO20064576L NO20064576L NO20064576A NO20064576A NO20064576L NO 20064576 L NO20064576 L NO 20064576L NO 20064576 A NO20064576 A NO 20064576A NO 20064576 A NO20064576 A NO 20064576A NO 20064576 L NO20064576 L NO 20064576L
- Authority
- NO
- Norway
- Prior art keywords
- cell growth
- treatment
- aberrant cell
- pyrimidine derivatives
- compounds
- Prior art date
Links
- 230000001594 aberrant effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Det beskrives forbindelser av formel (1) hvor R1-R4 er som definert heri. Slike nye pyrimidinderivater er nyttige i behandling av avvikende cellevekst, så som cancer, i et pattedyr. Oppfinnelsen vedrører også en fremgangsmåte for å benytte slike forbindelser i avvikende cellevekst i et pattedyr, spesielt mennesker, og farmasøytiske materialer inneholdende slike forbindelser.Compounds of formula (1) are described, wherein R 1 -R 4 is as defined herein. Such new pyrimidine derivatives are useful in the treatment of aberrant cell growth, such as cancer, in a mammal. The invention also relates to a method for utilizing such compounds in aberrant cell growth in a mammal, especially humans, and pharmaceutical materials containing such compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57131204P | 2004-05-14 | 2004-05-14 | |
| PCT/IB2005/001201 WO2005111023A1 (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064576L true NO20064576L (en) | 2006-11-07 |
Family
ID=34966230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064576A NO20064576L (en) | 2004-05-14 | 2006-10-09 | Pyrimidine derivatives for the treatment of aberrant cell growth |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1751143A1 (en) |
| JP (1) | JP4099212B2 (en) |
| KR (1) | KR100886990B1 (en) |
| CN (2) | CN1953974A (en) |
| AP (1) | AP2241A (en) |
| AR (1) | AR049097A1 (en) |
| AU (2) | AU2005243397A1 (en) |
| BR (1) | BRPI0511138A (en) |
| CA (1) | CA2566707A1 (en) |
| CR (1) | CR8749A (en) |
| EA (1) | EA200601796A1 (en) |
| EC (1) | ECSP066997A (en) |
| GE (1) | GEP20104875B (en) |
| GT (1) | GT200500113A (en) |
| IL (1) | IL178828A0 (en) |
| MA (1) | MA28583B1 (en) |
| MX (1) | MXPA06011890A (en) |
| NL (2) | NL1029045C2 (en) |
| NO (1) | NO20064576L (en) |
| NZ (1) | NZ550448A (en) |
| PA (1) | PA8632601A1 (en) |
| PE (1) | PE20060240A1 (en) |
| TN (1) | TNSN06370A1 (en) |
| TW (1) | TWI303635B (en) |
| UY (1) | UY28894A1 (en) |
| WO (1) | WO2005111023A1 (en) |
| ZA (1) | ZA200608394B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4812763B2 (en) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| EA014551B1 (en) * | 2005-12-21 | 2010-12-30 | Пфайзер Продактс Инк. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP4782239B2 (en) * | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | Sulfonylamide derivatives for the treatment of abnormal cell proliferation |
| CA2693594A1 (en) * | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| EP2231620A1 (en) * | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| PT2300013T (en) * | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Phosphorous derivatives as kinase inhibitors |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2014174745A1 (en) * | 2013-04-26 | 2014-10-30 | 国立大学法人京都大学 | Eg5 INHIBITOR |
| CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | ERK inhibitor containing isoindolinone and preparation method and use thereof |
| CN111732548B (en) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof |
| WO2024140671A1 (en) * | 2022-12-29 | 2024-07-04 | 南京昕瑞再生医药科技有限公司 | Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MXPA06002608A (en) * | 2002-12-20 | 2007-01-23 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-05-02 WO PCT/IB2005/001201 patent/WO2005111023A1/en not_active Ceased
- 2005-05-02 AU AU2005243397A patent/AU2005243397A1/en not_active Abandoned
- 2005-05-02 CN CNA2005800155302A patent/CN1953974A/en active Pending
- 2005-05-02 EP EP05732043A patent/EP1751143A1/en not_active Withdrawn
- 2005-05-02 AP AP2006003790A patent/AP2241A/en active
- 2005-05-02 GE GEAP20059703A patent/GEP20104875B/en unknown
- 2005-05-02 CN CN2011100212904A patent/CN102127058A/en active Pending
- 2005-05-02 JP JP2007512557A patent/JP4099212B2/en not_active Expired - Lifetime
- 2005-05-02 NZ NZ550448A patent/NZ550448A/en not_active IP Right Cessation
- 2005-05-02 MX MXPA06011890A patent/MXPA06011890A/en unknown
- 2005-05-02 KR KR1020067023767A patent/KR100886990B1/en not_active Expired - Lifetime
- 2005-05-02 BR BRPI0511138-2A patent/BRPI0511138A/en not_active IP Right Cessation
- 2005-05-02 CA CA002566707A patent/CA2566707A1/en not_active Abandoned
- 2005-05-02 EA EA200601796A patent/EA200601796A1/en unknown
- 2005-05-11 TW TW094115237A patent/TWI303635B/en not_active IP Right Cessation
- 2005-05-11 PA PA20058632601A patent/PA8632601A1/en unknown
- 2005-05-12 PE PE2005000534A patent/PE20060240A1/en not_active Application Discontinuation
- 2005-05-12 UY UY28894A patent/UY28894A1/en not_active Application Discontinuation
- 2005-05-13 NL NL1029045A patent/NL1029045C2/en not_active IP Right Cessation
- 2005-05-13 AR ARP050101969A patent/AR049097A1/en not_active Application Discontinuation
- 2005-05-13 GT GT200500113A patent/GT200500113A/en unknown
-
2006
- 2006-05-19 NL NL1031845A patent/NL1031845C2/en not_active IP Right Cessation
- 2006-10-06 ZA ZA200608394A patent/ZA200608394B/en unknown
- 2006-10-09 NO NO20064576A patent/NO20064576L/en not_active Application Discontinuation
- 2006-10-23 IL IL178828A patent/IL178828A0/en unknown
- 2006-11-13 TN TNP2006000370A patent/TNSN06370A1/en unknown
- 2006-11-13 EC EC2006006997A patent/ECSP066997A/en unknown
- 2006-11-13 CR CR8749A patent/CR8749A/en not_active Application Discontinuation
- 2006-11-14 MA MA29452A patent/MA28583B1/en unknown
-
2009
- 2009-11-13 AU AU2009238255A patent/AU2009238255A1/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064576L (en) | Pyrimidine derivatives for the treatment of aberrant cell growth | |
| NO20054852L (en) | GFAT inhibitors | |
| NO20082338L (en) | Pyrimidine derivatives for the treatment of aberrant cell growth | |
| NO20061432L (en) | N3 alkylated benzimidazole derivatives as MEK inhibitors | |
| NO20092033L (en) | New connections | |
| NO20080789L (en) | 1,4-benzothiazepine 1,1-dioxide derivatives, process for their preparation, medicaments containing this compound and its use as a hypolipid | |
| NO20083114L (en) | Polycyclic indazole derivatives which are ERK inhibitors | |
| NO20055421L (en) | Quinoline derivatives as phosphodiesterase inhibitors | |
| NO20050921L (en) | New physiologically active substances | |
| NO20050828L (en) | indole-3-sulfur derivatives | |
| NO20061506L (en) | Heterocyclic inhibitors of MEK and methods for their use | |
| NO20080728L (en) | New 1,4-benzothiazepine-1,1-dioxide derivatives having improved properties, process for their preparation, medicaments containing said compounds and use thereof | |
| NO20071137L (en) | New piperidine derivatives for the treatment of depression | |
| NO20091548L (en) | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors of diabetes | |
| NO20051303L (en) | New benzoimidazole derivatives useful as antiproliferative agents | |
| TNSN06074A1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| ATE454152T1 (en) | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF-KINASE INHIBITORS | |
| NO20063928L (en) | Substituted quinoline compounds | |
| NO20076196L (en) | New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidemic conditions | |
| NO20056192L (en) | Capase inhibitors and their use | |
| NO20055688L (en) | Organic compounds | |
| NO20082077L (en) | Spirocyclic quinazoline derivatives as PDE7 inhibitors | |
| NO20063821L (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| NO20055977L (en) | New benzimidazole derivatives | |
| NO20061839L (en) | Benzimidazole derivatives, compositions containing them, their preparation, and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |